The trajectory of therapeutic innovation in the Subcutaneous Neurofibroma Market is poised for significant shifts, necessitating meticulous market forecasting to anticipate the impact of emerging pipeline assets and changes in clinical practice. While surgical excision is the current mainstay, the field is rapidly advancing with systemic therapies, primarily MEK inhibitors, and other...